Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway

Wan Li; Jie Yi; Xiangjin Zheng; Shiwei Liu; Weiqi Fu; Liwen Ren; Li Li; Dave S B Hoon; Jinhua Wang; Guanhua Du

doi:10.1186/s13148-022-01317-4

Correction: miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway

Clin Epigenetics. 2022 Jul 29;14(1):97. doi: 10.1186/s13148-022-01317-4.

Authors

Wan Li^#^{1

2}, Jie Yi^#³, Xiangjin Zheng^{1

2}, Shiwei Liu⁴, Weiqi Fu^{1

2}, Liwen Ren^{1

2}, Li Li², Dave S B Hoon⁵, Jinhua Wang^{6

7}, Guanhua Du^{8

9}

Affiliations

¹ The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China.
² Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China.
³ Department of Clinical Laboratory, Peking Union Medical College Hospital, Beijing, 100730, China.
⁴ Department of Endocrinology, Shanxi DAYI Hospital, Shanxi Medical University, Taiyuan, 030002, Shanxi, China.
⁵ Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa Monica, CA, 90404, USA.
⁶ The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China. wjh@imm.ac.cn.
⁷ Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China. wjh@imm.ac.cn.
⁸ The State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing, China. dugh@imm.ac.cn.
⁹ Key Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, 100050, China. dugh@imm.ac.cn.

^# Contributed equally.

No abstract available

Publication types

Published Erratum